Triplex DNA Nanoswitch for pH-Sensitive Release of Multiple Cancer Drugs

ACS Nano ◽  
2019 ◽  
Vol 13 (6) ◽  
pp. 7333-7344 ◽  
Author(s):  
Xiaoxia Chen ◽  
Tianshu Chen ◽  
Lingjie Ren ◽  
Guifang Chen ◽  
Xiaohu Gao ◽  
...  
Keyword(s):  
Ph Sensitive ◽  
Triplex Dna ◽  
Cancer Drugs ◽  
Multiple Cancer

scholarly journals pH-Sensitive Ratiometric Fluorescent Probe for Evaluation of Tumor Treatments

Materials ◽  
2019 ◽  
Vol 12 (10) ◽  
pp. 1632
Author(s):  
Peisen Zhang ◽  
Junli Meng ◽  
Yingying Li ◽  
Zihua Wang ◽  
Yi Hou
Keyword(s):  
Ph Sensitive ◽  
Fluorescent Imaging ◽  
Tat Peptide ◽  
Cancer Drugs ◽  
Ph Response ◽  
In Vivo Experiments ◽  
Anti Cancer ◽  
Amidation Reaction

Determining therapeutic efficacy is critical for tumor precision theranostics. In order to monitor the efficacy of anti-cancer drugs (e.g., Paclitaxel), a pH-sensitive ratiometric fluorescent imaging probe was constructed. The pH-sensitive ratiometric fluorescent dye ANNA was covalently coupled to the N-terminal of the cell-penetrating TAT peptide through an amidation reaction (TAT-ANNA). The in vitro cellular experiments determined that the TAT-ANNA probe could penetrate the cell membrane and image the intracellular pH in real time. The in vivo experiments were then carried out, and the ratiometric pH response to the state of the tumor was recorded immediately after medication. The TAT-ANNA probe was successfully used to monitor the pharmacodynamics of anti-cancer drugs in vivo.

scholarly journals MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling

Cell ◽  
2012 ◽  
Vol 151 (5) ◽  
pp. 937-950 ◽  
Author(s):  
Sidong Huang ◽  
Michael Hölzel ◽  
Theo Knijnenburg ◽  
Andreas Schlicker ◽  
Paul Roepman ◽  
...  
Keyword(s):  
Receptor Signaling ◽  
Cancer Drugs ◽  
Multiple Cancer ◽  
Β Receptor

Dual-vectors of anti-cancer drugs and genes based on pH-sensitive micelles self-assembled from hybrid polypeptide copolymers

2011 ◽  
Vol 21 (9) ◽  
pp. 3100 ◽  
Author(s):  
Yong-Yong Li ◽  
Shou-Hu Hua ◽  
Wang Xiao ◽  
Hui-Yuan Wang ◽  
Xiao-Hua Luo ◽  
...  
Keyword(s):  
Ph Sensitive ◽  
Cancer Drugs ◽  
Anti Cancer ◽  
Self Assembled

Delivering anti-cancer drugs with endosomal pH-sensitive anti-cancer liposomes

2016 ◽  
Vol 4 (4) ◽  
pp. 627-638 ◽  
Author(s):  
Gopikrishna Moku ◽  
Suresh Kumar Gulla ◽  
Narendra Varma Nimmu ◽  
Sara Khalid ◽  
Arabinda Chaudhuri
Keyword(s):  
Drug Carriers ◽  
Ph Sensitive ◽  
Acidic Ph ◽  
Cancer Drugs ◽  
Tumor Tissues ◽  
Anti Cancer ◽  
Endosomal Ph

Numerous prior studies have been reported on the use of pH-sensitive drug carriers such as micelles, liposomes, peptides, polymers, nanoparticles,etc. that are sensitive to the acidic (pH = ∼6.5) microenvironments of tumor tissues.

scholarly journals Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials

2019 ◽  
Vol 11 (509) ◽  
pp. eaaw8412 ◽  
Author(s):  
Ann Lin ◽  
Christopher J. Giuliano ◽  
Ann Palladino ◽  
Kristen M. John ◽  
Connor Abramowicz ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Mechanism Of Action ◽  
Drug Targets ◽  
New Drugs ◽  
Common Mechanism ◽  
Cancer Drugs ◽  
Multiple Cancer ◽  
Target Deconvolution ◽  
Common Causes ◽  
Cancer Types

Ninety-seven percent of drug-indication pairs that are tested in clinical trials in oncology never advance to receive U.S. Food and Drug Administration approval. While lack of efficacy and dose-limiting toxicities are the most common causes of trial failure, the reason(s) why so many new drugs encounter these problems is not well understood. Using CRISPR-Cas9 mutagenesis, we investigated a set of cancer drugs and drug targets in various stages of clinical testing. We show that—contrary to previous reports obtained predominantly with RNA interference and small-molecule inhibitors—the proteins ostensibly targeted by these drugs are nonessential for cancer cell proliferation. Moreover, the efficacy of each drug that we tested was unaffected by the loss of its putative target, indicating that these compounds kill cells via off-target effects. By applying a genetic target-deconvolution strategy, we found that the mischaracterized anticancer agent OTS964 is actually a potent inhibitor of the cyclin-dependent kinase CDK11 and that multiple cancer types are addicted to CDK11 expression. We suggest that stringent genetic validation of the mechanism of action of cancer drugs in the preclinical setting may decrease the number of therapies tested in human patients that fail to provide any clinical benefit.

CMS to Cover Some Off-Label Cancer Drugs

2005 ◽  
Vol 38 (21) ◽  
pp. 55
Author(s):  
Joyce Frieden
Keyword(s):  
Cancer Drugs ◽  
Off Label
Sign in / Sign up

Export Citation Format

Share Document